Area of research
Pulmonary and Respiratory Medicine · Gastroenterology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Gastrointestinal Tumor Research and Treatment, Soft tissue tumor case studies, and Soft tissue tumors and treatment.
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial
Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?
67MO Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the phase III DeFi trial
Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
Musculoskeletal Metastasis From Soft-tissue Sarcomas: A Review of the Literature
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the <scp>INVICTUS</scp> Study
Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable
Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma.
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients
INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor